Full Press Release Details
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in October:
Pharma Partnering U.S. Summit (October 16-17, 2024)
Format: In-person (one-on-one meetings only)
Location: Hilton Boston Woburn, Boston, MA
Lisata representative: Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel at Lisata
Mr. Imam will be participating in one-on-one meetings at this event. If interested in meeting, please send a meeting request through the online partnering platform. For more information on the Pharma Partnering U.S. Summit and how to register, please click here or contact missy@pharma-partnering-summit.co.uk.
BioFuture (October 28-30, 2024; Virtual: November 5-7, 2024)
Format: In-person/Virtual
Location: Cure by Deerfield, New York, NY
Presentation Date: Monday, October 28, 2024
Presentation Time: 11:00 a.m. Eastern Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer at Lisata
For more information on BioFuture and how to register, please click here or contact info@demy-colton.com.
17th Annual LD Micro Main Event (October 28-30, 2024)
Format: In-person/Virtual
Location: Luxe Sunset Blvd Hotel, Los Angeles, CA
Presentation Date: Tuesday, October 29, 2024
Presentation Time: 11:00 a.m. Pacific Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
Register to watch the virtual presentation: https://me24.sequireevents.com
For more information on the LD Micro Main Event and how to register, please click here or contact registration@ldmicro.com.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit www.lisata.com.
Lisata Therapeutics, Inc.
Vice President, Investor Relations and Corporate Communications
Email: jmenditto@lisata.com